New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 8 #4 April 2005


STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER

PANCREATIC CANCER PART VI
IMMUNOTHERAPY/VACCINES

IMMUNOTHERAPY CHALLENGES IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
  • Defects in the Cellular Immune Response in PDAC
  • Animal Models

ACTIVE-SPECIFIC IMMUNOTHERAPY

  • Autologous Cell Vaccines
    • APC8024
    • Fowlpox-CEA-TRICOM
    • Human chorionic gonadotropin ß (hCGß) vaccine
    • Mutant ras peptide vaccine
    • Oncophage
  • Allogeneic Tumor-cell Vaccines
    • GVAX
    • NemodDC
  • Peptide/Antigen Vaccines
    • Avicine
    • GV1001
    • Insegia
    • Mesothelin-specific vaccine
    • MUC1 100-mer peptide vaccine
    • MUC1/IL-18 DNA vaccine
    • Panvac-VF
    • SAI-TGF-alpha

MONOCLONAL ANTIBODIES (MAB)

  • Binding Bodies
  • Other MAb-based Vaccines
    • PankoMab
    • HuABL-364
    • IGN-1

IMMUNOMODULATION/IMMUNOSTIMULATION

  • Cytokines
    • Interleukin-12 (IL-12)
    • Interferon alpha (IFN-alpha)
    • OncoVEX GM-CSF
  • Other Immunomodulators
    • Reximmune
    • Virulizin


LIST OF EXHIBITS

Exhibit 1 - Immunotherapies in Clinical or Preclinical Development for the Treatment of Pancreatic Cancer

Exhibit 2 - Selected Antigens in PDAC Immunotherapies


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887